Assertio Therapeutics Inc

Assertio Holdings, Inc. engages in the provision of commercial pharmaceutical products. Its commercial portfolio of branded products focuses on the following areas: neurology, hospital, and pain and inflammation. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Assertio Therapeutics Inc reports stellar Q4 performance and growth outlook

Assertio Therapeutics Inc (ASRT) delivered a robust Q4 performance with significant revenue and profit growth, despite facing challenges like supply issues.
The company's strategic focus on marketing, product development, and business expansion highlights a commitment to long-term success and shareholder value.
With a positive outlook for 2023 and a strong foundation in place, ASRT is poised for continued growth and value creation in the pharmaceutical market.

Assertio Therapeutics Inc (ASRT) reports robust Q1 results and raises 2023 guidance

Assertio Therapeutics Inc (ASRT) demonstrated solid financial performance in Q1 2023, with strong sales growth and improved profitability.
The company's strategic execution and upcoming acquisitions signal a positive outlook for future growth and expansion.
While facing integration challenges and market competition, Assertio's focus on product sales and operational efficiency bodes well for sustained success.

Assertio Therapeutics reports strong Q2 growth amidst generic competition

Assertio's Q2 performance showcased growth driven by key products and the acquisition of Spectrum Pharmaceuticals, positioning the company for future success.
While facing challenges from generic competition and operational expenses, Assertio remains focused on defending market share and creating shareholder value.
Management's confidence in overcoming short-term obstacles underscores a proactive approach to navigating market dynamics and driving growth.

Assertio Therapeutics Inc reports resilient Q3 performance amidst challenges

Assertio Therapeutics Inc navigated challenges in Q3 2023 with resilience, reporting positive financial metrics and improved liquidity.
New management changes and a focus on market access signal the company's commitment to driving growth and optimizing operations.
Despite lower sales for certain products, Assertio's strategic initiatives and financial performance position it well for future opportunities.
Analyst inquiries during the call highlighted areas for improvement and growth, indicating a proactive approach to addressing market dynamics.

Assertio Therapeutics reports robust Q4 results and outlines growth plans

Assertio Therapeutics Inc (ASRT) demonstrated strong financial performance in Q4 2023, driven by robust sales and positive EBITDA.
The company's strategic focus on Rolvedon's growth, profitability optimization, and future acquisitions positions it well for continued success.
While facing challenges from generic competition and operational issues, Assertio is poised to capitalize on growth opportunities and drive value creation.

Assertio Therapeutics Inc meets Q1 targets, eyes growth opportunities

Assertio Therapeutics Inc's Q1 2024 showcased strong sales performance, cost management, and cash generation. Despite challenges in generic competition and CEO transition, the company remains focused on growth opportunities.

Assertio Therapeutics reports solid Q2 results and projects growth

Assertio Therapeutics Inc (ASRT) demonstrated financial stability, growth potential, and resilience in the face of market challenges during Q2 2024.
The company's strategic focus on key products like Rolvedon and effective cost management strategies position it well for future success and profitability.
Maintaining guidance for 2024 and leveraging opportunities for growth underscore Assertio's commitment to delivering value to shareholders and stakeholders.

Assertio Therapeutics reports stable Q3 performance amid ROLVEDON transition

Assertio Therapeutics demonstrated stable financial performance and operational efficiency in Q3 2024, positioning the company for growth amidst challenges.
The company's focus on ROLVEDON and governance enhancements signal a strategic shift towards innovation and stakeholder value creation.
While facing challenges such as declining product sales and financial constraints, Assertio remains resilient and poised to capitalize on opportunities for growth and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The firm focuses on portfolio of neurology, inflammation, and pain medications. Its products include INDOCIN, Sympazan, Otrexup, SPRIX, CAMBIA, and Zipsor. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

A shocking M&A move tanked the stock, but it is recovering. Some are skeptical about the newly-acquired product, but it is better than a blockbuster rival.

Assertio Holdings: A Little More Risk, A Lot Higher Reward

The world's foremost artificial intelligence stock trading algorithm, An-E, predicts that Assertio (NASDAQ: ASRT ) stock will gain 3% by June 1. An-E (pronounced Annie) has made this kind of prediction before.

Artificial Intelligence Engine Predicts ASRT Stock to Gain 3% by June 1

Assertio Holdings stock has fallen 8.15% since my updated bullish thesis in March 2023, while the S&P 500 Index has gained 4.95% over the same period. The SPPI deal is expected to give Assertio access to Rolvedon and be accretive to adjusted EPS and operating cash flow in FY2024.

Assertio Holdings Stock Is Still A Cheap Buy

Spectrum Pharma

NEW YORK , April 27, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Spectrum Pharmaceuticals, Inc. ("Spectrum Pharmaceuticals" or the "Company") (NASDAQ: SPPI), in connection with its acquisition by Assertio Holdings, Inc. (NASDAQ: ASRT) ("Assertio"). Under the merger agreement, the Company's shareholders will receive 0.1783 shares of Assertio common stock for each of their shares, representing implied per-share consideration of $0.89 based upon Assertio's April 26, 2023 closing price of $5.00.

SHAREHOLDER ALERT: Weiss Law Investigates Spectrum Pharmaceuticals, Inc.

NEW YORK , April 27, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ: ASRT), in connection with its proposed merger with Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) ("Spectrum Pharmaceuticals"). If you own Assertio  shares  and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website: https://www.weisslaw.co/news-and-cases/asrt   Or please contact: Joshua Rubin, Esq.

SHAREHOLDER ALERT: Weiss Law Investigates Assertio Holdings, Inc.

LAKE FOREST, Ill., April 27, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that it will release first quarter 2023 financial results on Tuesday, May 9, 2023, after the market close. Following the release of its financial results, Assertio's management will host a live webcast of the earnings conference call at 4:30 p.m. Eastern Time.

Assertio Holdings, Inc. to Report First Quarter 2023 Financial Results on Tuesday, May 9, 2023

Spectrum Pharmaceuticals (NASDAQ:SPPI) stock is soaring after an all-stock acquisition deal with Assertio Holdings was announced Tuesday morning.  The $248 million purchase price values Spectrum shares at $1.14 each, a significant premium over its Tuesday closing price of $0.69.

Spectrum Pharmaceuticals stock pops after Assertio acquires it at a premium

Complementary Commercial Growth Platforms Anticipated to Accelerate ROLVEDON™ (eflapegrastim-xnst) Injection Profitability and Diversify Revenue Streams

Assertio Holdings, Inc. to Acquire Spectrum Pharmaceuticals, Inc. in All Stock and CVR Transaction

SYMPAZAN (clobazam) oral CIV film from Assertio is used for the adjunctive treatment of seizures associated with LGS in patients two years of age and older

Assertio Provides Educational Grant for New Lennox-Gastaut Syndrome (LGS) Foundation Treatments Kits

Assertio (ASRT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Investors Heavily Search Assertio Holdings, Inc. (ASRT): Here is What You Need to Know

Since my previous bullish article on ASRT stock, it has gained 68.54% and continues thriving. Time to update my thesis. Thanks to the addition of 2 new drugs to its sales structure, which now account for over 8% of total sales, ASRT increased its top line by almost 42% [YoY].

Assertio Holdings Stock: The Rally Is Likely Not Over Yet

Assertio Holdings, Inc. has impressive growth rates and an attractive valuation. The company's involvement with an opioid in the past may explain the low valuation.

Assertio Holdings: Spectacular Growth Story Powered By Risky Strategy

Adobe

Alpha Metallurgical Resources

Companies with strong profitability tend to have more stable earnings and cash flows, which can make them more resilient to market volatility. This article focuses on stocks with a proven track record of profitability. High-quality stocks come in all shapes and sizes regardless of their market cap.

Eternal Sunshine: 3 Very Profitable Stocks To Buy In 2023

Recently, Zacks.com users have been paying close attention to Assertio (ASRT). This makes it worthwhile to examine what the stock has in store.

Here is What to Know Beyond Why Assertio Holdings, Inc. (ASRT) is a Trending Stock

Is Trending Stock Assertio Holdings, Inc. (ASRT) a Buy Now?

Assertio Holdings, Inc. (NASDAQ:ASRT ) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Company Participants Matt Kreps - Darrow Associates, Investor Relations Dan Peisert - President & Chief Executive Officer Paul Schwichtenberg - Senior Vice President & Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Scott Henry - ROTH Capital Hamed Khorsand - BWS Financial Mitra Ramgopal - Sidoti Operator Good afternoon and welcome to the Assertio Holdings' Fourth Quarter and Full Year 2022 Financial Results Conference Call. All participants are now in listen-only mode.

Assertio Holdings, Inc. (ASRT) Q4 2022 Earnings Call Transcript

Assertio (ASRT) delivered earnings and revenue surprises of 482.61% and 1.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Assertio (ASRT) Tops Q4 Earnings and Revenue Estimates

Net Product Sales Increase 55% in the Fourth Quarter, 42% for the Full Year

Assertio Reports Fourth Quarter and Full Year 2022 Financial Results

LAKE FOREST, Ill., March 06, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced the appointment of Howard J. Franklin, MD, as Senior Vice President, Medical.

Assertio Appoints Dr. Howard Franklin as Senior Vice President, Medical

Assertio Holdings, Inc. (ASRT) is Attracting Investor Attention: Here is What You Should Know

Assertio (ASRT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Assertio (ASRT)

Assertio (ASRT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Assertio (ASRT) Reports Next Week: Wall Street Expects Earnings Growth

Assertio (ASRT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Assertio (ASRT) Soars 5.1%: Is Further Upside Left in the Stock?

Assertio is a truly impressive turnaround story that is now set to grow, mostly through M&A. The crucial ingredient is the digital-only sales model, which puts acquired drugs on a much lower cost basis while maintaining sales.

Assertio: A Truly Impressive Turnaround Story

Q4 preliminary results illustrate the best product sales quarter for the past 5 years. Technicals, valuation, and profitability trends all point to rising prices for the stock.

News for Assertio Therapeutics Inc Stock (ASRT)